ArticleCureus2026
Clinical Characteristics, Prognostic Factors, and Outcomes of Patients With Medullary Thyroid Carcinoma: A Retrospective Review From a Tertiary Care Hospital.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMedullary thyroid carcinoma (MTC) is an uncommon neuroendocrine tumor of the thyroid with a highly variable clinical course. Epidemiological and outcome data on MTC from South Asian countries are limited. This study was conducted to assess the clinical features, treatment approaches, and outcomes of patients with MTC managed at a tertiary care hospital in Pakistan.
methodsWe performed a retrospective observational study including adult patients with histologically confirmed MTC treated between December 2008 and December 2019. Data collected included demographics, tumor characteristics, multiple endocrine neoplasia type 2 (MEN2) status, biochemical markers, treatment modalities, and survival outcomes. Postoperative serum calcitonin and carcinoembryonic antigen (CEA) levels, along with calcitonin doubling time (DT), were evaluated as prognostic indicators. Statistical analyses were performed using Statistical Package for the Social Sciences version 26.0 (IBM Corp., Armonk, NY).
resultsWe found a total of 90 patients having MTC during our study period, as the prevalence is scarce, so all the patients found were included (mean age = 39.3 ± 12.3 years (17-67); 43.3% male). MEN2A-associated disease was present in 13.3%. Cervical lymph node involvement and distant metastases were observed in 37.8% and 13.3% of patients, respectively. Disease-free status strongly correlated with improved overall survival (p < 0.001). Elevated post-treatment calcitonin and CEA levels, as well as shorter calcitonin DT, were associated with poorer survival. Patients with distant metastases, particularly bone involvement, had significantly worse outcomes (p < 0.001).
conclusionEarly disease detection, achievement of disease-free status, and favorable postoperative biochemical markers are key predictors of survival in MTC. These findings underscore the importance of timely diagnosis and comprehensive management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.